Browsing ICR Divisions by author "Semiannikova, Maria"
Now showing items 1-6 of 6
-
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
Gonzalez-Exposito, R; Semiannikova, M; Griffiths, B; Khan, K; Barber, LJ; et al. (BMJ PUBLISHING GROUP, 2019-03-21)BACKGROUND: The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high ... -
Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes.
Challoner, BR; von Loga, K; Woolston, A; Griffiths, B; Sivamanoharan, N; et al. (OXFORD UNIV PRESS INC, 2021-01-04)BACKGROUND: Gastric and gastro-esophageal junction cancers (GCs) frequently recur after resection, but markers to predict recurrence risk are missing. T-cell infiltrates have been validated as prognostic markers in other ... -
Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts.
Ferrari, N; Ranftl, R; Chicherova, I; Slaven, ND; Moeendarbary, E; et al. (NATURE PUBLISHING GROUP, 2019-01-10)Aggressive behaviours of solid tumours are highly influenced by the tumour microenvironment. Multiple signalling pathways can affect the normal function of stromal fibroblasts in tumours, but how these events are coordinated ... -
Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer.
von Loga, K; Woolston, A; Punta, M; Barber, LJ; Griffiths, B; et al. (NATURE PUBLISHING GROUP, 2020-01-16)Mismatch repair deficient (dMMR) gastro-oesophageal adenocarcinomas (GOAs) show better outcomes than their MMR-proficient counterparts and high immunotherapy sensitivity. The hypermutator-phenotype of dMMR tumours theoretically ... -
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey, A; Griffiths, B; Michaux, J; Pak, HS; Stevenson, BJ; et al. (BMC, 2019-10-08)BACKGROUND: Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomics ... -
Investigating determinants of sensitivity and resistance to T cell redirecting antibodies in colorectal cancer through patient derived organoid models
Gerlinger M; Semiannikova, M; Gerlinger, M (Institute of Cancer Research (University Of London), 2023-06-12)Most colorectal cancers (CRCs) do not respond to treatment with immune-checkpoint-inhibitors due to modest mutation loads, low cytotoxic T cell infiltrates, and immunosuppressive microenvironments. The CEA-TCB bispecific ...